ADC Therapeutics signals data catalysts ahead with ZYNLONTA combinations, aims for regulatory milestones through 2025

Stock Information for ADC Therapeutics SA

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ADC Therapeutics SA

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)
ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028
ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics to Present at Upcoming Investor Conferences
ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)
ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.